Abstract
ObjectivesThe prognosis for women with recurrent or persistent EC after progressing on first-line chemotherapy is poor. The humanized monoclonal anti-programmed cell death ligand 1 (PD-L1) inhibitor, Atezo has demonstrated monotherapy...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have